Sign in

You're signed outSign in or to get full access.

Michael [Indiscernible]

Research Analyst at Individual Investor

I'm sorry, but after a thorough search, I was unable to locate a Michael with a discernible last name who works as an analyst at Individual Investor, nor could I find a LinkedIn profile matching those criteria. Without a full name or more specific details, I am unable to provide an accurate professional profile or associated credentials. Please provide a complete name or additional details to proceed with your request.

Michael [Indiscernible]'s questions to 111 (YI) leadership

Question · Q2 2024

Asked about the number of new and total patents the company holds, and for details on the private label business, including the number of products and future growth plans.

Answer

The company secured 4 new patents in the quarter, bringing the total to 28, many of which relate to AI applications like voice recognition and photo-based drug retrieval. On private labels, there are about 200 SKUs across several brands. This business is a key margin contributor for both 111 and its pharmacy customers. The company will continue to invest in this area, with more products in the pipeline for OTC, RX, supplements, and medical devices.

Ask follow-up questions

Fintool

Fintool can predict 111 logo YI's earnings beat/miss a week before the call